+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Cimzia - Product Thumbnail Image

Cimzia

  • Report
  • July 2018
  • 65 Pages
From
Global Rheumatoid Arthritis Drugs Market 2022-2026 - Product Thumbnail Image

Global Rheumatoid Arthritis Drugs Market 2022-2026

  • Report
  • April 2022
  • 120 Pages
From
Antiepileptic Drugs Market - Forecast (2022 - 2027) - Product Thumbnail Image

Antiepileptic Drugs Market - Forecast (2022 - 2027)

  • Report
  • January 2022
  • 137 Pages
From
From
From
Psoriasis - Pipeline Insight, 2021 - Product Thumbnail Image

Psoriasis - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 200 Pages
From
From
Global Krabbe Disease Treatment Market 2022-2026 - Product Thumbnail Image

Global Krabbe Disease Treatment Market 2022-2026

  • Report
  • April 2022
  • 120 Pages
From
Global Parkinsons Disease (PD) Drugs Market 2020-2024 - Product Thumbnail Image

Global Parkinsons Disease (PD) Drugs Market 2020-2024

  • Report
  • January 2021
  • 120 Pages
From
From
From
Loading Indicator